This study was performed to compare the pharmacological characteristics of propofol in an emulsion of both medium-and long-chain triglycerides (MCT/LCT) with those of propofol in an LCT emulsion, by measuring the sedative level and the plasma concentration of propofol during sedation using a target-controlled infusion (TCI) technique. Forty ASA 1 or 2 adult patients who required spinal anaesthesia for surgery were enrolled in this study. The patients were divided into two groups: a propofol LCT group (n=20) and a propofol MCT/LCT group (n=20). Propofol was injected intravenously at target blood concentrations of 2.0, 3.0 and 4.0 µg.ml -1 . The bispectral (BIS®) index was recorded, and arterial blood was drawn to measure the actual plasma concentrations of propofol at each predicted concentration. Propofol was assayed by high-performance liquid chromatography. Propofol MCT/LCT was associated with significantly less pain than propofol LCT (P<0.05). There were no significant differences between the two groups in BIS® index or in plasma concentration of propofol at each predicted concentration. Computergenerated TCI of propofol MCT/LCT during sedation is comparable with that of propofol LCT with respect to pharmacokinetics and pharmacodynamics. The formulation of MCT/LCT has a beneficial effect with respect to less pain on injection.
Propofol has traditionally been formulated at a concentration of 10 mg.ml -1 in a fat emulsion (Intralipid®; Fresenius Kabi, Oslo, Norway) consisting of 10% soybean oil long-chain triglyceride (LCT) (Diprivan®; AstraZeneca, London, U.K.). Although LCT has not been associated with known anaphylactoid reactions, moderate to severe pain on injection is still a problem in 28 to 90% of patients [1] [2] [3] . It has been shown that high concentrations of free propofol in the aqueous phase of an emulsion are associated with pain on injection 4, 5 and that dilution of this formulation with additional Intralipid® decreased the incidence and intensity of pain on injection 5 .
Since 1995, propofol in an emulsion of 50% medium-chain triglyceride (MCT) and 50% LCT (Lipuro®; B. Braun AG, Melsungen, Germany) has been used clinically, especially in Europe and Japan 4, 5 . This modified emulsion can decrease the concentration of free propofol in the aqueous phase of the emulsion 6 . On the other hand, disodium edetate (EDTA) at 0.005 wt/vol% concentration has been included in propofol LCT since 1996 because of its bacteriostatic effect 7 . It is anticipated that the pharmacokinetics and pharmacodynamics of the anaesthetic might be different in clinical use 8 . Therefore, this study was performed to compare the pharmacological characteristics of propofol MCT/LCT with those of propofol formulated in an LCT fat emulsion by measuring the sedative level by the use of bispectral (BIS®) index monitoring and the plasma concentration of propofol by high-performance liquid chromatography during sedation under spinal anaesthesia with a target-controlled infusion (TCI) technique.
METHODS
This study was approved by our institutional Ethics Committee on Human Research, and written informed consent for participation in the study was obtained from each patient. Forty ASA physical status 1 or 2 adult patients (40 to 60 years) who underwent spinal anaesthesia for elective urological surgery were enrolled in this study. Patients with a history of, or in whom results of laboratory tests or physical examinations indicated the presence of, hepatic, renal or significant disorders of the central nervous system such as Alzheimer's disease or cerebral infarction were excluded from the study. The patients were randomly divided by a sealed envelope technique into two groups: a propofol LCT (Diprivan® 1%; AstraZeneca Japan, Osaka, Japan) group (n=20) and a propofol MCT/LCT (1% propofol "Maruishi" inj.; Maruishi, Osaka, Japan) group (n=20). The investigators and patients were blinded to the preparations administered, and all of the formulations were of the same colour.
Patients received no premedication. An intravenous catheter was inserted into an antecubital vein in the left arm, and each patient received a rapid infusion of 8 ml.kg -1 of acetated Ringer's solution. Standard monitoring included continuous electrocardiography and pulse oximetry. Noninvasive arterial pressure and heart rate were recorded at one minute intervals for 20 minutes after induction of anaesthesia and every five minutes thereafter by an automated noninvasive oscillometer. Lumbar puncture was performed in the lateral position at the L3-L4 vertebral interspace. Ten milligrams of tetracaine diluted in an equal volume (2.0 ml) of 10% dextrose was injected over a period of 10 s in every patient. After completion of injection, the patient was immediately returned to the supine position. A preload of 4 ml.kg -1 of acetated Ringer's solution was given over a 20minute period, and a maintenance of the same crystalloid solution was then run at a rate of 4 ml.kg -1 .h -1 throughout surgery. Block height was assessed by pinprick testing at 5 and 20 min after blockade. Hypotension was defined as systolic arterial pressure (SAP) of less than 90 mmHg or a decrease of more than 25% from the baseline. After having reached one of these criteria, patients were treated with rescue IV bolus doses of ephedrine in 5 mg increments until SAP above these thresholds was established. The patient was placed in the lithotomy position for surgery.
A left radial artery catheter was inserted with local anaesthesia to obtain blood samples for subsequent measurement of plasma concentrations of propofol. The BIS sensor of a BIS monitor (A2000; Aspect Medical Systems, Newton, MA, U.S.A.) was then placed on either the right or the left hemisphere. After monitoring the control value of BIS index, propofol was injected intravenously at an initial target concentration of 2.0 µg.ml -1 by the use of a computer-generated TCI technique. A laptop computer-controlled Graseby 3500 ® pump (SIMS Graseby Ltd., Watford, Herts, U.K.) was used to obtain the desired effect compartment (blood) concentration of propofol using BeConSim ® software ver. 4.3.87b (developed by Dr Ken-ichi Masui, M.D., Department of Anesthesiology, Yamanashi University School of Medicine, Kofu, Yamanashi, Japan). The pharmacokinetic parameters employed in the software (open, three-compartment model) are the same as those in Diprifusor ® (Master TCI, Fresenius Vial, Brezins, France) 9 . The maximum infusion rate was 1,200 ml.h -1 . The patients were asked to describe the sensation during injection of propofol: no pain or mild, moderate, or severe pain (almost intolerable). After reaching both the predicted plasma concentration of 2.0 µg.ml -1 and the predicted effect site (brain) concentration of within 95% of 2.0 µg.ml -1 , the BIS index was recorded and arterial blood was drawn to measure the actual plasma concentrations of propofol. The target concentration of the pump was then changed to 3.0 µg.ml -1 and 4.0 µg.ml -1 according to a protocol similar to that for the concentration of 2.0 µg.ml -1 . During sedation, each patient received 3 l.min -1 oxygen via a face mask. When the study was finished, the infusion of propofol was discontinued and the recovery time was measured. The recovery time was defined as the duration between the discontinuation of propofol infusion and the time of eye opening on verbal command. Propofol was assayed using liquid-liquid extraction followed by reversephase high-performance liquid chromatography with fluorescence detection (ECD-100 equipped with an EP-10 pump and a DG-100 degasser; Eicom, Tokyo, Japan), as described by Chan and So 10 . The lower limit of detection was 2.0 ng.ml -1 .
Sample size was determined by power analysis on the basis of the results of a previous study by Beller et al 11 , who examined blood propofol concentrations in relation to recovery times in patients in the ICU sedated with propofol. Considering an equivalence range within 10%, and accepting a type 1 error of 0.05 and a type II error of 0.1, enough patients to obtain at least 18 complete data sets per group for this study. Data are expressed as numbers (%), medians (range) or means±SDs. Statistics were performed with unpaired Student's t-test to compare demographic data, and the plasma concentrations of propofol and BIS indices between the two groups. Repeated measures analysis of variance with Fisher's PLSD (post hoc least significant difference) test for multiple comparisons was performed to compare BIS indices and plasma concentrations of propofol with increase in target concentration. The χ 2 -test and Fisher's exact test were used to analyze the incidence and intensity of pain on injection between the two groups, respectively. For all comparisons, differences were rated significant at P<0.05. All pharmacological calculations and statistical analyses were performed using Statview™ 4.02 (SAS Institute Inc., Cary, CA, U.S.A.).
RESULTS
Twenty patients were enrolled in each group, and all patients completed the study. Demographic characteristics, baseline haemodynamic data and dermatomal sensory levels are presented in Table 1 . The two groups were similar in age, weight, height, ASA physical status, sex distribution, level of sensory block at 20 minutes and baseline haemodynamic variables. Subjective ratings of pain after the propofol infusion, incidences of the pain on the injection, incidences of hypotension during the study, and recovery times are shown in Table 2 . The results showed that propofol MCT/LCT was associated with significantly less incidence and less intensity of pain on injection than the standard preparation of propofol LCT (P=0.043 and 0.047, respectively), whereas the recovery times and the incidences of hypotension in the two groups were indistinguishable (P=0.82 and 0.88, respectively).
The measured plasma concentrations of propofol and the BIS indices at TCI of predicted 2.0, 3.0 and 4.0 µg.ml -1 in each group are shown in Figure 1 . With an increase in the predicted plasma concentrations of propofol by a computer-controlled pump, the plasma concentrations of propofol measured by chromatography increased concomitant with a decrease in BIS indices (P<0.05; between 2.0 and 3.0 µg.ml -1 , and between 3.0 and 4.0 µg.ml -1 predicted plasma concentrations of propofol). There were no significant differences in these parameters between the groups.
DISCUSSION
The use of a modified emulsion formulation requires a new pharmacological study, because preparations using different formulations may result in varying pharmacodynamic and kinetic characteristics 8 . This randomized, controlled, double-blinded, prospective study demonstrated that the pharmacological properties of 1% propofol diluted in an MCT/LCT solvent are indistinguishable from those of 1% propofol LCT. Since age is an important factor in determining the sedative level induced by propofol 12 , we selected subjects with a small range of ages (40-60 years old). The results obtained in this study are consistent with those reported previously 13, 14 . Dutta et al 8 reported that the nature of the formulation could profoundly influence the clinical characteristics of intravenously administered drugs by modifying the pharmacokinetics or pharmacodynamics or both. This discrepancy seems to be due to the different formulation that they used (lipid-free formulation). Müller and Harnisch 6 reported that the total content of propofol was according to the specification of 1% (=10.0 mg.ml -1 ); the values analysed ranged from 9.51 to 10.34 mg.ml -1 . The contents of free propofol in the water phase were very similar at approximately 20 µg.ml - Data are expressed as numbers, means±SDs, or medians (range). ASA: American Society of Anesthesiologists. LCT: long-chain triglyceride. MCT: medium-chain triglyceride. LCT) apart from one. A low content of free propofol of only 14.0 mg.ml -1 was analysed in the propofol MCT/LCT emulsion. Even though the concentration of free propofol is different between the two kinds of propofol agent, the plasma concentration of free propofol after injection seem to be indistinguishable as shown in this study. Pain during injection of propofol in a traditional fat emulsion (propofol LCT) is a common adverse reaction. There have been some comparative studies on pain on injection with propofol MCT/LCT in adults 14, 15 and children 16 . The results of these studies are consistent with those obtained in this TCI study. Pain during an IV bolus injection of propofol is a common problem 2,3 . Because lignocaine is absorbed by the fat emulsion, a lignocaine-propofol mixture must be used quickly after preparation to ensure the anaesthetic effect of lignocaine in the vein 17 . For slow infusion, propofol also may be diluted in a 5% glucose solution 17 . Both the incidence and intensity of pain on injection in this TCI study were less than those reported previously. This is because propofol was diluted with continuous infusion of acetated Ringer's solution. Considering the benefits of a minimized free drug in the water phase, the propofol MCT/LCT emulsion is considered to be the most tolerable system when using TCI.
The accuracy of Diprifusor TCI meets the standards required for clinical purposes with respect to 1) control of the depth of anaesthesia and 2) formal measurement of predictive performance 18 . This study showed consistently that Diprifusor TCI delivers the required anaesthetic effect when a particular target concentration of the drug is selected. The control of anaesthesia is more important than the specific blood concentration achieved. However, standardization of device performance provides reassurance that drug delivery is reproducible at a particular target setting. It has been proposed that median absolute performance error (MDAPE), a measure of precision, should be no greater than 20% to 40% for the performance of a TCI system to be clinically acceptable and that median performance error (MDPE), a measure of bias, should be no greater than 10% to 20% 19 . There were no significant differences in these parameters between the groups.
